Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

531
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
531
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

904
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
904
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

748
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
748
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

961
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
961

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden.

Advanced healthcare materials·2026
Same author

The Long and Winding Road: The Resilience of Cervical Cytology as a Long-Standing Laboratory Tool to Aid the Diagnosis of Human Papillomavirus-Induced Lesions.

Acta cytologica·2026
Same author

Mechanical behavior of human breast tissues: ex vivo and in silico characterization.

Biomechanics and modeling in mechanobiology·2026
Same author

Frizzled-9 Expression Is Associated With Aggressive Clinicopathological Features and Reduced Overall Survival in Invasive Breast Carcinoma.

Pathology international·2026
Same author

Purpura fulminans following a dog bite.

Intensive care medicine·2026
Same author

Evaluation and Recommendations to Modernize Cervical Cancer Detection and Prevention Programs in Brazil: Challenges and Opportunities - A Narrative Review.

Acta cytologica·2026

Related Experiment Video

Updated: Jan 18, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.8K

Branched-Chain Amino Acids Exacerbate Colitis Progression by Lowering Colonic Fumarate Levels.

Ana Mendes-Frias1,2, Maria C Vieira1,2, Marta Araújo1,2

  • 1Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.

Inflammatory Bowel Diseases
|September 10, 2025
PubMed
Summary
This summary is machine-generated.

Branched-chain amino acid (BCAA) supplementation worsened colitis in mice by altering gut microbiota and metabolites. Dimethyl fumarate (DMF) showed promise in mitigating these adverse effects, highlighting caution for BCAA use in inflammatory conditions.

Keywords:
branched-chain amino acidsfumarateulcerative colitis

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.2K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.6K

Related Experiment Videos

Last Updated: Jan 18, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.8K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.2K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.6K

Area of Science:

  • Gastroenterology and Immunology
  • Microbiome Research
  • Metabolomics

Background:

  • Ulcerative colitis (UC) etiology is unclear, but metabolites are crucial for gut health.
  • Previous studies indicated enriched colonic branched-chain amino acids (BCAAs) in colitis-resistant mice.
  • This suggests a potential role for BCAAs in UC development.

Purpose of the Study:

  • To investigate the impact of BCAA supplementation on dextran sulfate sodium (DSS)-induced colitis in mice.
  • To explore the underlying mechanisms involving gut microbiota and metabolomic changes.
  • To evaluate the therapeutic potential of dimethyl fumarate (DMF) in mitigating BCAA-induced colitis exacerbation.

Main Methods:

  • Mice received BCAA supplementation followed by DSS-induced colitis.
  • Evaluated disease activity index (DAI), immune cell profiling, histology, and transcriptomics.
  • Conducted 16S rRNA sequencing, metabolomic profiling, and DMF treatment intervention.

Main Results:

  • BCAA supplementation exacerbated colitis, increasing DAI and histological damage.
  • Observed altered immune cell populations (decreased ILC3, increased Th17/Treg) and gut microbiota shifts (decreased Lactobacillus, increased pathobionts).
  • Metabolomic analysis revealed reduced colonic fumarate and increased pro-inflammatory metabolites; DMF treatment attenuated these effects.

Conclusions:

  • BCAA supplementation exacerbates DSS-induced colitis via detrimental gut microbiota and metabolome alterations.
  • DMF treatment effectively mitigated BCAA-induced inflammation and improved disease outcomes.
  • Findings emphasize caution with BCAAs during inflammation and highlight microbiome-targeted therapies for UC.